AI Article Synopsis
- * There is ongoing research focused on developing therapies that can control HIV-1 without ART, leveraging advancements like chimeric antigen receptor (CAR) cell therapy, which has shown promise in treating blood cancers.
- * This review highlights the progress made in CAR cell therapy for HIV-1 over the past 20 years, including necessary modifications to protect CAR cells from HIV-1 infection, and discusses the current state of CAR therapies moving toward clinical trials for HIV-1.
Article Abstract
Antiretroviral therapy (ART) for HIV-1 has dramatically improved outcomes for people living with HIV-1 but requires life-long adherence and can be associated with short and long-term toxicity. Numerous pre-clinical and clinical investigations are underway to develop therapies for immune control of HIV-1 in the absence of ART. The success of chimeric antigen receptor (CAR) cell therapy for hematological malignancy has renewed efforts to develop and investigate CAR cells as strategies to enhance HIV-1 immunity, enable virus control or elimination, and allow ART-free HIV-1 remission. Here, we review the improvements in anti-HIV-1 CAR cell therapy in the two decades since their initial clinical trials were conducted, describe the additional engineering required to protect CAR cells from HIV-1 infection, and preview the current landscape of CAR cell therapies advancing to HIV-1 clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241028 | PMC |
| http://dx.doi.org/10.1016/j.jve.2022.100073 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!